Core Viewpoint - The company Shijiazhuang Pharmaceutical Group has received production registration approvals from the National Medical Products Administration of China for several pharmaceutical products, indicating significant progress in its product portfolio and market positioning [1] Group 1: Product Approvals - The company has obtained production registration for Aminophylline Tablets (100mg), classified as a Class 3 chemical drug, making it the third domestic company to receive such approval [1] - Aminophylline Tablets are primarily used for alleviating symptoms of bronchial asthma, asthmatic bronchitis, and obstructive pulmonary emphysema, and can also treat asthma caused by cardiogenic pulmonary edema [1] - The company's raw material for Aminophylline has also been approved for use in marketed formulations by the National Medical Products Administration [1] Group 2: Additional Product Approvals - The company has also secured production registration for Hydrochloride of Picarbital Inhalation Solution (0.5ml: 50μg) and Injection of Dihydrosodium Adenosine Triphosphate (0.5g), classified as Class 3 and Class 4 chemical drugs respectively [1] - Hydrochloride of Picarbital Inhalation Solution is mainly used to relieve symptoms associated with bronchial asthma, chronic bronchitis, and emphysema with airflow limitation [1] - Injection of Dihydrosodium Adenosine Triphosphate is primarily used for treating intrahepatic cholestasis caused by liver cirrhosis and cholestasis during pregnancy [1]
石四药集团已取得国家药监局有关氨茶硷片的药品生产注册批件